Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Next Previous
Trial Profile

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirikizumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 03 Oct 2019 Planned End Date changed from 22 Sep 2019 to 28 Oct 2019.
    • 03 Oct 2019 Planned primary completion date changed from 22 Sep 2019 to 28 Oct 2019.
    • 16 Aug 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top